According to the Zhītōng Cáijīng APP, Genscript Bio (01548) fell more than 4%, down 3.67% to HKD 12.08 at the time of publication, with a turnover of HKD 0.168 billion and a total market value of over HKD 25 billion.

On the news front, Legend Biotech recently received a merger invitation and hired investment bank Centerview Partners to help its board of directors review the acquisition offer and other options. It is reported that Legend Biotech is a subsidiary of Genscript Bio, with Genscript Bio holding a stake of 47.96%. According to industry speculation, if this potential acquisition is calculated at a 30%-50% premium, the acquisition price could be between USD 13-15 billion, and after the sale is completed, Genscript Bio could receive cash of approximately RMB 45.19-52.14 billion.

Some analysts have said that Legend Biotech has always been the most imaginative business sector of Genscript Bio, and investors have been waiting for Carvykti to achieve heavy sales and reap huge dividends from long-term overseas sales. If Legend Biotech is finally sold, the cash it generates will far exceed Genscript's current market cap. However, creating another Legend Biotech is not easy, and the company faces the risk of "shellization" in the future.